Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 09/16/22 | EFFECT | Notice of Effectiveness |
|
1 | |
| 09/16/22 | 8-K | Current report filing |
|
   |
3 |
| 09/14/22 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 09/02/22 | UPLOAD | SEC-generated letter |
|
1 | |
| 08/31/22 | S-3 | Registration statement for specified transactions by certain issuers |
|
15 | |
| 08/25/22 | 8-K | Current report filing |
|
|
2 |
| 08/25/22 | DEF 14A | Definitive proxy statements |
|
12 | |
| 08/19/22 | D | Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act. |
|
6 | |
| 08/15/22 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
12 | |
| 08/15/22 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
21 |
